Viking Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Viking Therapeutics filed its 2023 10-K, detailing financial agreements and stock-based compensation.</b>

AI Summary

Viking Therapeutics, Inc. (VKTX) filed a Annual Report (10-K) with the SEC on February 7, 2024. Viking Therapeutics, Inc. filed its 2023 Form 10-K on February 7, 2024, reporting on its fiscal year ended December 31, 2023. The filing details various agreements including a Commitment Purchase Agreement and Registration Rights Agreement with Lincoln Park Capital Fund, L.P. The company's fiscal year ends on December 31st annually. Key dates mentioned include April 13, 2016, for an Over-Allotment Option and September 28, 2027, for common stock related agreements. The filing references stock-based compensation plans, including Performance-Based Restricted Stock Units (PRSUs) and employee stock options.

Why It Matters

For investors and stakeholders tracking Viking Therapeutics, Inc., this filing contains several important signals. The 10-K filing provides a comprehensive overview of Viking Therapeutics' financial health, operational status, and strategic agreements for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. Details on stock-based compensation, including PRSUs and employee stock options, offer insight into management incentives and potential dilution, which are key considerations for shareholders.

Risk Assessment

Risk Level: medium — Viking Therapeutics, Inc. shows moderate risk based on this filing. The company is in the pharmaceutical industry, which is subject to significant regulatory hurdles, lengthy development timelines, and high R&D costs, as evidenced by the nature of its business and the typical risks associated with drug development.

Analyst Insight

Investors should review the detailed risk factors and financial statements within the 10-K to understand the company's operational and financial standing, particularly concerning its drug development pipeline and associated funding requirements.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-02-07 — Filing Date (Date of submission)
• 001-37355 — SEC File Number (Viking Therapeutics' SEC file number)

Key Players & Entities

• Viking Therapeutics, Inc. (company) — Filer name
• Lincoln Park Capital Fund, L.P. (company) — Party to Commitment Purchase Agreement and Registration Rights Agreement
• 2023-12-31 (date) — Fiscal year end
• 2024-02-07 (date) — Filing date

Forward-Looking Statements

• Viking Therapeutics will likely utilize its commitment purchase agreement with Lincoln Park Capital Fund, LLC to raise capital for ongoing research and development. (Viking Therapeutics, Inc.) — medium confidence, target: 2027-09-28
• The common stock of Viking Therapeutics may experience dilution as shares are sold under the agreement with Lincoln Park Capital Fund, LLC. (Viking Therapeutics, Inc.) — medium confidence, target: 2027-09-28

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive government regulation, which can impact product development, manufacturing, and marketing.
• Funding Requirements [high — financial]: The company requires substantial capital for research, development, and commercialization of its product candidates.
• Clinical Trial Risks [high — operational]: The success of drug development is uncertain, with significant risks associated with the outcomes of clinical trials.

Industry Context

Viking Therapeutics operates in the biopharmaceutical sector, focusing on the development of novel therapeutics for metabolic and endocrine diseases.

Regulatory Implications

The biopharmaceutical industry is heavily regulated by agencies like the FDA, requiring rigorous testing and approval processes for new drugs.

What Investors Should Do

1. Analyze the company's financial statements and cash flow for the fiscal year ended December 31, 2023.
2. Review the details of the various agreements mentioned, such as the Commitment Purchase Agreement and Registration Rights Agreement.
3. Assess the company's progress and risks associated with its drug development pipeline as outlined in the risk factors section.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-02-07: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing analyzed, so no prior filing data is available for comparison.

Key Financial Figures

• $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar

Filing Documents

• vktx-20231231.htm (10-K) — 2597KB
• vktx-ex10_11.htm (EX-10.11) — 33KB
• vktx-ex23_1.htm (EX-23.1) — 3KB
• vktx-ex31_1.htm (EX-31.1) — 15KB
• vktx-ex31_2.htm (EX-31.2) — 15KB
• vktx-ex32_1.htm (EX-32.1) — 12KB
• vktx-ex97.htm (EX-97) — 54KB
• img253267218_0.jpg (GRAPHIC) — 117KB
• 0000950170-24-012322.txt (&nbsp;) — 10450KB
• vktx-20231231.xsd (EX-101.SCH) — 1229KB
• vktx-20231231_htm.xml (XML) — 1910KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 21 Item 1B. Unresolved Staff Comments 56 Item 1C. Cybersecurity 57 Item 2.

Properties

Properties 58 Item 3.

Legal Proceedings

Legal Proceedings 58 Item 4. Mine Safety Disclosures 58 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 59 Item 6. [Reserved] 59 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 60 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 67 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 67 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 67 Item 9A.

Controls and Procedures

Controls and Procedures 68 Item 9B. Other Information 69 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 69 PART III Item 10. Directors, Executive Officers and Corporate Governance 70 Item 11.

Executive Compensation

Executive Compensation 70 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 70 Item 13. Certain Relationships and Related Transactions, and Director Independence 70 Item 14. Principal Accounting Fees and Services 70 PART IV Item 15. Exhibits, Financial Statement Schedules 71 Item 16. Form 10-K Summary 73 i This Annual Report on Form 10-K contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in connection with the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially and adversely from those expressed or implied by such forward-looking statements. Such forward-looking statements include estimates of our expenses, future revenue, capital requirements and our needs for additional financing; statements regarding our ability to develop, acquire and advance drug candidates into, and successfully complete, clinical trials and preclinical studies; statements concerning new product candidates; risks and uncertainties associated with our research and development activities, including our clinical trials and preclinical studies; our expectations regarding the potential market size and the size of the patient populations for our drug candidates, if approved for commercial use, and our ability to serve such markets; statements regarding our ability to maintain and establish collaborations or obtain additional funding; statements regarding developments and projections relating to our competitors and our industry and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "

Busi ness

Item 1. Busi ness. Overview We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, or TR. In November 2019, we initiated the VOYAGE study, a Phase 2b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis, or NASH. The VOYAGE study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3. The primary endpoint of the study will evaluate the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction, or MRI-PDFF, from baseline to week 12 in subjects treated with VK2809 as compared to placebo. Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of dosing. In January 2023, we announced completion of patient enrollment in the VOYAGE study and in May 2023 we reported that the VOYAGE study successfully achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared to placebo. Results from the biopsy after 52 weeks of dosing are expected to be available in 2024. VK2809 has been evaluated in eight completed clinical studies, which enrolled more than 300 subjects. No serious adverse events, or SAEs, have been observed in subjects receiving VK2809 in these completed studies, and overall tolerability remains encouraging. In addition, the compound has been evaluated in chronic toxicity studies of up to 12 months in duration. In January 2022, we announced the initiation of a Phase 1 single ascending dos

View Full Filing

View this 10-K filing on SEC EDGAR